Polaryx Therapeutics, Inc. Common Stock (PLYX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has a cash flow conversion efficiency ratio of -0.326x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.49 Million) by net assets ($4.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Polaryx Therapeutics, Inc. Common Stock balance sheet quality to measure how much of total assets are equity-financed.
Polaryx Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore PLYX debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Polaryx Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Consórcio Alfa de Administração S.A
SA:BRGE3
|
0.031x |
|
WiSoL CO.LTD
KQ:122990
|
0.024x |
|
Tainergy Tech Co Ltd
TW:4934
|
-0.035x |
|
We&Win Diversification Co Ltd
TWO:4113
|
-0.061x |
|
Nordhealth AS
OL:NORDH
|
-0.008x |
|
Taseco Air Services JSC
VN:AST
|
0.091x |
|
GR Silver Mining Ltd
V:GRSL
|
-0.097x |
|
Suria Capital Holdings Bhd
KLSE:6521
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual cash flow conversion efficiency of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Polaryx Therapeutics, Inc. Common Stock.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.57 Million | $-3.94 Million | -0.864x | -58.22% |
| 2024-12-31 | $4.71 Million | $-2.57 Million | -0.546x | -303.07% |
| 2023-12-31 | $1.28 Million | $-173.00K | -0.135x | -- |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more